Explaining the Serological Characteristics of Streptococcus suis Serotypes 1 and 1/2 from Their Capsular Polysaccharide Structure and Biosynthesis

Calsteren, Marie‐Rose Van; Goyette-Desjardins, Guillaume; Gagnon, Fleur; Okura, Masatoshi; Takamatsu, Daisuke; Roy, René; Gottschalk, Marcelo; Segura, Mariela

doi:10.1074/jbc.m115.700716

Cited by 33 publications

(60 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this property was not observed herein using a ST25 strain: as such, it would be interesting to confirm using other cell types. It is important to note that composition and structure are responsible for serotype determination [ 42 , 46 ], and that all serotype 2 strains have the same CPS antigenically, which indicates a highly similar structure and composition. In addition, the cps locus is identical in all serotype 2 strains sequenced to date, regardless of sequence type [ 47 ].…”

Section: Discussionmentioning

confidence: 99%

Role of the Streptococcus suis serotype 2 capsular polysaccharide in the interactions with dendritic cells is strain-dependent but remains critical for virulence

et al. 2018

Self Cite

View full text Add to dashboard Cite

Streptococcus suis serotype 2 is an important porcine bacterial pathogen and zoonotic agent responsible for sudden death, septic shock, and meningitis. However, serotype 2 strains are heterogeneous, composed of a multitude of sequence types (STs) whose distribution greatly varies worldwide. Of the virulence factors presently described for S. suis, the capsular polysaccharide (CPS) is a critical factor implicated in a multitude of functions, including in impairment of phagocytosis and innate immune cell activation by masking underlying bacterial components. However, these roles have been described using Eurasian ST1 and ST7 strains, which greatly differ from North American ST25 strains. Consequently, the capacity of the CPS to mask surface antigens and putative virulence factors in non-Eurasian strains remains unknown. Herein, the role of the S. suis serotype 2 CPS of a prototype intermediate virulent North American ST25 strain, in comparison with that of a virulent European ST1 strain, with regards to interactions with dendritic cells, as well as virulence during the systemic phase of infection, was evaluated. Results demonstrated that the CPS remains critical for virulence and development of clinical disease regardless of strain background, due to its requirement for survival in blood. However, its role in the interactions with dendritic cells is strain-dependent. Consequently, certain key characteristics associated with the CPS are not necessarily applicable to all S. suis serotype 2 strains. This indicates that though certain factors may be important for S. suis serotype 2 virulence, strain background could be as determining, reiterating the need in using strains from varying backgrounds in order to better characterize the S. suis pathogenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Role of the Streptococcus suis serotype 2 capsular polysaccharide in the interactions with dendritic cells is strain-dependent but remains critical for virulence

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Depending on the sensitivity of the specific CPS to hydrolysis, two methods of CPS extraction were used. For serotypes 2, 1, 1/2, and 3, the autoclave method was used (23,28,30).…”

Section: S Suis Capsular Polysaccharidesproduction and Purificationmentioning

confidence: 99%

Comparative Study of Immunogenic Properties of Purified Capsular Polysaccharides fromStreptococcus suisSerotypes 3, 7, 8, and 9: the Serotype 3 Polysaccharide Induces an Opsonizing IgG Response

et al. 2020

Self Cite

View full text Add to dashboard Cite

Streptococcus suis is an encapsulated bacterium and one of the most important swine pathogens and a zoonotic agent for which no effective vaccine exists. Bacterial capsular polysaccharides (CPSs) are poorly immunogenic, but anti-CPS antibodies are essential to the host defense against encapsulated bacteria. In addition to the previously known serotypes 2 and 14, that are non-immunogenic, we have recently purified and described the CPS structures for serotypes 1, 1/2, 3, 7, 8, and 9. Here, we aimed to elucidate how these new structurally diverse CPSs interact with the immune system to generate anti-CPS antibody responses. CPS-stimulated dendritic cells produced significant levels of C–C motif chemokine ligand (CCL) 3, partially via Toll-like receptor (TLR) 2- and myeloid differentiation factor 88-dependent pathways, and CCL2, via TLR-independent mechanisms. Mice immunized with purified serotype 3 CPS adjuvanted with TiterMax Gold® produced an opsonizing IgG response, whereas other CPSs or adjuvants were negative. Mice hyperimmunized with heat-killed S. suis serotypes 3 and 9 both produced anti-CPS type 1 IgGs, whereas serotypes 7 and 8 remained negative. Also, mice infected with sublethal doses of S. suis serotype 3 produced primary anti-CPS IgM and IgG responses, of which only IgM were boosted after a secondary infection. In contrast, mice sublethaly infected with S. suis serotype 9 produced weak anti-CPS IgM and IgG responses following a secondary infection. This study provides important information on the divergent evolution of CPS serotypes with highly different structural and/or biochemical properties within S. suis and their interaction with the immune system.

show abstract

“…Goyette-Desjardins et al [51] characterized the protective activity of monoclonal antibodies (mAbs) directed against S. suis serotype 2 CPS. All mAbs targeted the sialylated chain of the CPS, but showed different cross-reactivity against S. suis serotypes 1, 1/2, and 14, whose CPS structures are similar to that of serotype 2 [52][53][54]. Only the immunoglobulin (Ig)G1 mAb was shown to be serotype 2-specific.…”

mentioning

confidence: 99%

Streptococcus suis Research: Progress and Challenges

Segura

2020

Pathogens

Self Cite

View full text Add to dashboard Cite

Streptococcus suis is considered among the top bacterial pathogens leading to important economic losses to the swine industry, with the incidence of disease increasing as the prophylactic use of antimicrobial is being vanished worldwide. S. suis is also a zoonotic agent afflicting people in close contact with infected pigs or pork meat. Besides, in some Asian countries, it is considered a major public health concern for the general population as well. Antimicrobial resistance is one of the most important global health challenges, and in the absence of preventive measures (such as effective vaccines), S. suis remains a risk for increased antimicrobial resistance and transmission of resistance genes to other bacteria beyond the host animal species. The studies in this Special Issue have evidenced the importance of swine population demographics and management on disease control, progress in molecular tools to better understand the epidemiology of S. suis infections in swine and humans, and the mechanisms involved in different aspects of the immuno-pathogenesis of the disease. The importance of reducing the prophylactic use of antimicrobials in livestock productions and the development of alternative control measures, including vaccination, are herein discussed.

show abstract

Explaining the Serological Characteristics of Streptococcus suis Serotypes 1 and 1/2 from Their Capsular Polysaccharide Structure and Biosynthesis

Cited by 33 publications

References 28 publications

Role of the Streptococcus suis serotype 2 capsular polysaccharide in the interactions with dendritic cells is strain-dependent but remains critical for virulence

Role of the Streptococcus suis serotype 2 capsular polysaccharide in the interactions with dendritic cells is strain-dependent but remains critical for virulence

Comparative Study of Immunogenic Properties of Purified Capsular Polysaccharides fromStreptococcus suisSerotypes 3, 7, 8, and 9: the Serotype 3 Polysaccharide Induces an Opsonizing IgG Response

Streptococcus suis Research: Progress and Challenges

Contact Info

Product

Resources

About